Background: Acute wheezing illnesses in preschoolers require better management strategies to reduce morbidity. Objectives: We sought to examine the effectiveness of episodic use of an inhaled corticosteroid and a leukotriene receptor antagonist in preschoolers with intermittent wheezing. Methods: In a randomized, double-blind, placebo-controlled 12month trial, 238 children aged 12 to 59 months with moderate-tosevere intermittent wheezing received 7 days of either budesonide inhalation suspension (1 mg twice daily), montelukast (4 mg daily), or placebo in addition to albuterol with each identified respiratory tract illness (RTI). Proportion of episode-free days (EFDs) during the 12-month trial was the primary outcome. Results: The 3 treatment groups did not differ in proportions of EFDs, with adjusted mean EFDs of 76% (95% CI, 70% to 81%) for budesonide, 73% (95% CI, 66% to 79%) for montelukast, and 74% (95% CI, 65% to 81%) for conventional therapy (P 5 .66). The 3 groups did not differ in oral corticosteroid use, health care use, quality of life, or linear growth. However, during RTIs, budesonide and montelukast therapy led to modest reductions in trouble breathing (38% [P 5 .003] and 37% [P 5 .003], respectively) and interference with activity scores (32% [P 5 .01] and 40% [P 5 .001], respectively) that were most evident in those with positive asthma predictive indices. Conclusions: In preschool children with moderate-to-severe intermittent wheezing, episodic use of either budesonide or montelukast early in RTIs, when added to albuterol, did not increase the proportion of EFDs or decrease oral corticosteroid use over a 12-month period. However, indicators of severity of acute illnesses were reduced, particularly in children with positive asthma predictive indices. (J Allergy Clin Immunol 2008;122:1127-35.) 
Abbreviations used
API: Asthma predictive index AUC: Area under the curve CARE: Childhood Asthma Research and Education EFD: Episode-free day ICS: Inhaled corticosteroid LTRA: Leukotriene receptor antagonist RTI: Respiratory tract illness Wheezing illnesses are frequent occurrences in preschool children, and many young children who wheeze repeatedly in the context of lower respiratory tract illnesses (RTIs) have severe exacerbations, even though these exacerbations are separated by extended periods of wellness. Rates for wheezing-related emergency department visits 1 and hospitalizations [1] [2] [3] [4] [5] are highest among children less than 5 years of age, reflecting not only the significant morbidity associated with these exacerbations but also the difficulty in treating wheezing illness in a way that might prevent progression of illness severity. Evidence for management strategies in this population is not consistent. The National Asthma Education and Prevention Program guidelines, recognizing the lack of convincing data on this subject, propose the consideration of episodic use of oral corticosteroids at the first sign of RTI as a treatment option in patients with histories of severe exacerbations 6 based on clinical experience and a study that was not a randomized controlled trial. 7 However, 3 randomized controlled trials of early use of oral corticosteroids demonstrated no effect on symptom scores, [8] [9] [10] [11] although the largest of these trials had low levels of adherence to the protocol. In addition, for those children in this age group who have several RTIs during a single respiratory viral season, parents are often reluctant to use oral corticosteroids for each of the episodes, and repeated courses of oral corticosteroids can be associated with significant side effects. [12] [13] [14] [15] Three studies suggested that initiating inhaled corticosteroid (ICS) therapy at the early signs of RTI does not result in reduction in oral corticosteroid use, [16] [17] [18] but these studies were small (22-55 subjects each) and used different time points for intervening with medication, thus limiting interpretation of results. An alternative treatment strategy, using montelukast episodically in children 2 to 14 years of age with intermittent asthma, was recently reported to lead to a reduction in unscheduled health care use, 19 along with modest reductions in symptom scores and nocturnal awakenings, without a reduction in oral corticosteroid use.
Based on these previously reported disparate results using different medications and treatment approaches, as well as parental and clinician reluctance to use frequent courses of oral corticosteroids, a large, double-blind, randomized controlled clinical trial was designed that would permit a comparison of 3 episodic treatment strategies initiated at the early signs of acute RTI on the course of moderate-to-severe intermittent wheezing over a 12-month period.
METHODS Patients
Patients were recruited between February and October 2004 at 5 clinical centers. The protocol was reviewed and approved by the Childhood Asthma Research and Education (CARE) Network Protocol Review Committee and then by the institutional review boards at each center. Written informed consent was obtained from the parents of each participant. The trial was monitored by the CARE Network Data and Safety Monitoring Board.
Inclusion criteria were age 12 to 59 months and having experienced at least 2 episodes of wheezing in the context of an RTI within the past year. One episode must have occurred within the past 6 months, and 1 episode must have been documented by a health care provider. In an effort to include children with prior moderate-to-severe wheezing episodes, children were required to have experienced either 2 urgent care visits for acute wheezing within the past year, 2 wheezing episodes for which oral corticosteroids were prescribed, or 1 episode requiring urgent care and 1 episode requiring oral corticosteroids. Children were excluded if, over the past year, they had received more than 6 courses of oral corticosteroids, were hospitalized more than twice for wheezing, or had used asthma controller medications (including ICSs, leukotriene receptor antagonists [LRTAs], cromolyn/nedocromil, or theophylline) for 4 or more months cumulative or within the preceding 2 weeks. Other exclusion criteria included birth before 36 weeks' gestational age, the presence of other significant lung or other medical conditions, gastroesophageal reflux under medical therapy, current antibiotic use for sinusitis, or a history of life-threatening wheezing episode.
Patients meeting all of the eligibility criteria were followed for 2 weeks, during which parents completed diary cards twice daily. Diary cards incorporated the validated Pediatric Asthma Caregiver Diary 20 and included 5 symptom categories (nocturnal cough, daytime cough, wheezing, difficulty breathing, and symptoms interfering with activities), each scored on a 0through 5-point scale (see Table E1 in this article's Online Repository at www.jacionline.org). Children were excluded if, during the 2-week observation period, parents completed diary cards on less than 80% of days, if asthma controller medications were used, or if the score for albuterol use, wheezing, difficulty breathing, nighttime cough, or asthma symptoms interfering with activities was 1 or greater or if the daytime cough score was greater than 2 on an average of 4 or more days per week.
Protocol
After completing the 2-week run-in/observation period, participants were randomly assigned to one of 3 parallel treatment groups. Participants received one of the following regimens for 7 days at the first sign of RTI-associated symptoms: (1) (3) conventional therapy group (placebo ICS twice daily and placebo LTRA once daily). Placebos were identical to active drugs in terms of appearance and taste and were also donated by the makers of the active agents. Nebulized medications were administered by using a PariLC Plus nebulizer (Midlothian, Va) and a tight-fitting face mask or mouthpiece, depending on the age of the child, because both delivery methods have been demonstrated to be comparably effective in improving clinical parameters in infants and young children. 21, 22 All participants received albuterol inhalation treatments (Proventil HFA administered through an AeroChamber with mask [Monhagan Medical Corp, Plattsburgh, NY], 180 mg per treatment, or Proventil nebulization solution, 2.5 mg/treatment [donated by Schering-Plough, Deerfield, Ill]) 4 times daily while awake (plus as needed) for the first 48 hours, followed by albuterol use on an as-needed basis. The same intervention treatment was repeated with each subsequent illness characterized by RTI-associated symptoms over the 12-month study period without a prespecified limit on the number of treatment courses. Oral corticosteroids (prednisolone) were available for all children at home and were started based on a specific algorithm (see Table E2 in this article's Online Repository at www.jacionline. org). 23 Other asthma medications were not permitted during RTI, but use of nonasthma medications was not restricted.
Based on the variability in the signs and symptoms of RTI that precede the development of significant wheezing, the individualized timing for starting study medications was derived according to an educational protocol designed and evaluated in a pilot study preceding the main trial (see the Methods section in this article's Online Repository at www.jacionline.org). Parents were instructed to begin a 7-day course of the study medication at the onset of the individualized set of symptoms identified as the child's starting point. Parents received extensive education at all study visits regarding close attention to the development of symptoms that were likely to represent an RTI followed by extension to chest symptoms.
The schedule of study procedures is detailed in the Methods section of this article's Online Repository. Clinic visits were scheduled 4 weeks after randomization and then every 8 weeks, whereas telephone calls were scheduled 2 weeks after randomization, followed by calls 4 weeks after each scheduled clinic visit.
Outcome measures
The primary outcome measure was the proportion of episode-free days (EFDs) over the study period as recorded on diary cards twice daily for the 12month trial. An EFD was defined as a day during which the child was free from cough, wheeze, trouble breathing, asthma-associated interference with daily activities or awakening from sleep, health care use caused by wheezing (unscheduled contact, urgent visit, emergency department visit, or hospitalization), and use of asthma-related nonstudy medications (including inhaled b-agonists, controller asthma medications other than study medications, and systemic corticosteroids). [24] [25] [26] Use of masked study medications was not used in determining EFDs. Secondary outcome measures included the severity of lower respiratory tract symptoms as reflected by the area under the curve (AUC) for symptom scores in the 14-day intervals after initiation of study medication. Other secondary outcomes included time to initiation of the first course of oral corticosteroids, the total number of oral corticosteroid courses, the number of wheezing episodes, days missed from day care and parental work, caregiver quality of life, number of unscheduled visits for acute wheezing episodes (primary care office, urgent care, and emergency department/hospitalization), and linear growth. The a priori analysis plan included examination of the effects of study interventions stratified by asthma predictive index (API) status, as determined at the randomization visit. Treatment failure was defined as the occurrence of 4 oral corticosteroid courses, hospitalization or intubation for wheezing, hypoxic seizure, or serious adverse events related to a study medication. Participants meeting treatment failure status were prescribed open-label budesonide, 0.5 mg once daily, for 6 weeks and returned to their primary care physician for further management.
An unequal allocation ratio was implemented, in which the budesonide and montelukast groups each were allocated twice as many randomized subjects as the conventional therapy group. Allowing for a 10% dropout rate, the targeted sample size of 225 randomized participants (90 per active therapy and 45 for conventional therapy) provided 90% statistical power for detecting an absolute effect size of 0.15 in each of the 2 primary comparisons of proportion of EFDs for active therapy versus conventional therapy by using a Bonferronicorrected, 2-tailed .025 significance level and 80% statistical power for detecting an effect size of 0.10 in the secondary comparison of the active therapies at the .05 significance level (2-tailed) . A previous study comparing oral steroids with control displayed mean proportions of 0.94 and 0.77, respectively, and served as the basis of the power calculation. 7 For the secondary outcomes, the targeted sample size provided 90% statistical power for detecting effect sizes of 0.5 SD units (active treatment vs conventional therapy) and 80% power to detect a difference of 30 EFDs per year between the 2 active treatment arms.
The randomization sequence was stratified according to center, age (12-23 months or 24-59 months), and API status (positive or negative 23 ) in blocks of 5 to maintain balanced treatment allocation within strata. Criteria for determination of API status are provided in Table E3 .
Statistical analyses
Baseline characteristics were summarized by using descriptive statistics and compared across treatments by using ANOVA for continuous measures and the x 2 test for categorical measures. Dropouts were more frequent in the montelukast group (12.6%) compared with the budesonide (5.2%) and conventional therapy (2.1%) groups (P 5 .04 across groups) and were predominantly caused by loss to follow-up.
The primary analysis of a child's proportion of EFDs was performed by using binomial regression, accounting for overdispersion with a quasilikelihood function, along with pairwise comparisons of the group proportions. Dropouts and treatment failures were included, treating days between treatment failure and scheduled study completion date as episode days, as specified a priori. Additional post hoc analyses were performed with 3 additional approaches to data related to treatment failure: (1) all days between treatment failure and termination as EFDs, (2) carrying the proportion of EFDs observed before treatment failure through to the termination date, and (3) using only available data before the treatment failure date. These 3 approaches provided qualitatively similar findings to the primary analysis.
Secondary outcomes of number of oral corticosteroid courses, days of oral corticosteroid use, number of urgent care and emergency department visits, and days missed from school or day care were analyzed by using Poisson regression analysis. Time to first prednisone course and time to treatment failure outcomes were analyzed by using proportional hazards regression. Growth (defined as change in height or length from baseline to study end) and quality-of-life outcomes were analyzed by using analysis of covariance.
The AUC was calculated by using the trapezoidal method for the 14 days after initiation of study medication (day 1) for symptom scores, excluding those who never used study medication. This value was analyzed as a difference from ''baseline'' symptom levels, defining baseline as twice the AUC from days 213 to 27, which preceded onset of symptoms to avoid any subtle increase in symptoms during the 7 days immediately preceding initiation of study medications. Group comparisons were made by using a mixed-effects linear model to account for repeated illnesses within children.
All analyses were performed with SAS Version 9.1 statistical software (SAS Institute, Inc, Cary, NC) and adjusted for the randomization strata. Reported P values for active versus conventional therapy comparisons for all outcomes were considered statistically significant if they were lower than .025 (Bonferroni correction for 2 primary comparisons), whereas P values for active therapy comparisons were compared to .05.
RESULTS

Subject characteristics
Of 351 patients enrolled, 238 were randomized, and 220 completed the trial or reached the criteria for treatment failure (Fig 1) . The 3 treatment groups were well matched for demographic features, pretrial morbidity (including health care use), atopic features, and baseline quality of life, with the exception Among those participants with an asthma diagnosis (number of participants noted in parentheses). àHighest possible score 5 7.
§Highest possible score 5 100.
of a higher proportions of male children in the budesonide and montelukast groups (Table I) . Further characteristics of this cohort have been described previously. 27 Children with positive API status exhibited features of greater morbidity in the preceding year, including greater numbers of wheezing illnesses, acute care visits, and numbers of courses of oral corticosteroids (see Table  E4 in this article's Online Repository at www.jacionline.org). The 3 groups were significantly different with respect to dropout rate (overall, P 5.04; montelukast greater than conventional therapy, P 5 .04) but were not significantly different with respect to the rate or time to treatment failure (P 5 .48 and P 5 .4, respectively), although the use of the intent-to-treat analysis strategy, along with use of all available data on dropouts, results in a minimal effect of these dropouts on the findings described herein.
Adherence
Adherence to the study medication regimens was estimated based on diary card recordings of illness kits used and counting returned medications. Children in the 3 treatment arms experienced comparable numbers of RTIs per child, with means of 3.4 (95% CI, 2.9-3.9), 3.7 (95% CI, 3.2-4.2), and 3.6 (95% CI, 3.0-4.3) for the montelukast, budesonide, and conventional therapy groups, respectively (total of 840 illnesses). Study medication kits were used for 95% of RTIs during the trial, and use did not differ by treatment arm. Study medication kits were not used for 1 of the RTIs by 23 participants, for 2 RTIs by 7 participants, and for 3 RTIs by 1 participant. Lack of use did not differ by treatment group. Diary cards were completed on a median of 89.5% of days (lower quartile, 67.1%; upper quartile, 96.4%).
Twelve-month global outcomes
The primary outcome measure, EFDs, did not differ significantly among the 3 treatment groups, reaching an adjusted mean of 76% (95% CI, 70% to 81%) EFDs in the budesonide group, 73% (95% CI, 66% to 79%) EFDs in the montelukast group, and 74% (95% CI, 65% to 81%) EFDs in the conventional therapy group (P 5 .66, Table II ). There were no significant interactions between treatment group and either API status (positive or negative, P 5 .71) or oral corticosteroid use in the preceding year (P 5 .49) with respect to the proportion of EFDs. During the 14 days after initiation of study medications for RTIs, 45% 6 20% of days were episode free and did not differ by treatment group. In contrast, during times when the child was not experiencing an RTI or using study medication, 82% 6 25% of days were episode free and did not differ by treatment group.
The 3 groups did not differ significantly in several other outcomes assessed over the 1-year trial (Table II) , including oral corticosteroid use (P 5 .15), health care use (P 5 .98), linear growth (P 5 .59), quality of life (P > .16), and frequencies of adverse events. There were 6 (6.3%), 2 (2.1%), and 4 (8.5%) hospitalizations in the montelukast, budesonide, and conventional therapy groups, respectively (P 5 .22).
Acute RTI outcomes
The a priori analysis plan included examination of the effects of study interventions during the 14 days after initiation of study medications for RTIs to determine the effects of treatment during RTIs in terms of illness severity and duration. Relative to conventional therapy, there were statistically significant reductions in trouble breathing score AUC (37.5% reduction for budesonide, P 5 .003; 36.8% reduction for montelukast, P 5 .003) and interference with activity AUC (31.9% reduction for budesonide, P 5 .01; 39.6% reduction for montelukast, P 5.001; Fig 2) . Wheezing score AUC was significantly reduced with montelukast therapy (33.5% reduction, P 5 .02) but not with budesonide (24.6% reduction, P 5 .09). Cough score AUCs did not differ by treatment group (P .12, see Table E5 in this article's Online Repository at www.jacionline.org). Total symptom score (wheeze plus cough plus interference with activity plus trouble breathing) AUC was significantly reduced with montelukast (29.6% reduction, P 5 .006) and budesonide (24.6% reduction, P 5 .02) therapy. There were no significant differences between budesonide and montelukast for any of these symptom measures (P > .4). Similar results were obtained when the AUCs were calculated over just the 7 days during which study medications were administered (data not shown).
Examination of the effect of the API status stratification factor on episode severity revealed that, among participants with positive API status, both budesonide and montelukast significantly reduced AUCs for trouble breathing scores (48.0% reduction for budesonide, P 5 .001; 40.3% reduction for montelukast, P 5 .007) and interference with activity scores (43.6% reduction for budesonide, P 5 .001; 53.7% reduction for montelukast, P < .001), whereas only montelukast significantly reduced the wheezing score AUC (P 5 .049, Table III ). Among participants with negative API status, neither active treatment led to significant reductions in AUCs compared with conventional therapy for any of the symptom scores. The interaction between treatment group and API status reached significance only for the montelukast group in terms of interference with the activity score AUC (P 5 .03). In a post hoc analysis similar findings were obtained when the cohort was stratified by oral corticosteroid use (0 vs 1 course) during the year preceding participation in the trial (see Table E6 in this article's Online Repository at www.jacionline.org).
DISCUSSION
We have demonstrated that, in preschool children with moderate-to-severe intermittent wheezing, neither budesonide nor montelukast initiated at early signs of RTI increase the proportion of EFDs over a 12-month period relative to conventional therapy, nor was there an effect on oral corticosteroid rescue, asthma health care use (urgent care visits, emergency department visits, or hospitalizations), or quality of life. However, budesonide or montelukast initiated at early signs of RTI significantly reduce episode severity relative to conventional therapy, with montelukast reducing wheezing, trouble breathing, and activity limitation and budesonide reducing trouble breathing and activity limitation, despite the use of 4-times-daily albuterol during the peak symptom period of the first 48 hours of illness. AUCs during RTIs. AUCs were calculated for the 14 days after initiation of study medication (shaded in dark gray) for symptom scores of trouble breathing (A), interference with activity (B), wheezing (C), daytime cough (D), and mean total symptom score (E). This value was analyzed as a difference from baseline symptom levels, defining baseline as twice the AUC from days 213 to 27, which preceded onset of symptoms (shaded in light gray). The tables present the AUCs (95% CIs) and P values comparing each active therapy with conventional therapy. There were no significant differences between montelukast and budesonide for any of these symptom measures (P > .4). *Mean of daytime cough plus wheezing plus trouble breathing plus interference with activity.
Our findings are consistent with a recent trial of episodic montelukast treatment in children 2 to 14 years of age with intermittent asthma, which noted modest reductions in symptom scores (14%) and nocturnal awakenings (8.6%) and a 28.5% reduction in unscheduled health care use 19 but no effect on use of oral corticosteroids or b-agonists. Conversely, another recent trial found no effect of ICSs initiated after 3 days of wheezing on episode severity in young children aged 1 month to 2 years, 28 although the lack of effect observed might have been due to the relatively late initiation of therapy relative to the onset of symptoms.
Our results extend these observations in at least 2 ways: first, we directly compared the effects of intervention with both ICSs and montelukast within the same trial, and second, we demonstrated a differential response during RTIs to both episodic ICS and LTRA therapy based on 2 indicators of heterogeneity in terms of baseline disease severity among the enrolled population: API status (a priori analysis) and prior oral corticosteroid use (post hoc analysis). Children with positive API status or prior oral corticosteroid use derived significantly greater benefit from study medications than children with negative API status or lack of prior oral corticosteroid use in terms of 40% to 54% reductions in episode severity, as reflected by trouble breathing and interference with activity scores AUC. The absence of detectable effect in the group with negative API status might be due, in part, to the smaller sample and effect sizes and thus lower power in this subgroup relative to those seen in the group with positive API status (94 vs 144 participants, respectively).
During the study, 82% of days outside of RTIs, corresponding to a mean of 5.74 EFDs per week, were considered EFDs, confirming the low frequency of asthma-like symptoms outside of episodes that were severe. These findings corroborate clinical experience for the existence of a ''severe intermittent wheezing'' 27 phenotype in early childhood (ie, children with low impairment but high risk). The new findings of more clinical benefit being demonstrable in a subgroup of these children (those with positive API status) raises an important clinical question. Should these children with positive API status be treated episodically, given the evidence for some benefits to be gained during the wheezing episode, or should they be treated as if they had persistent asthma, with daily long-term control medication?
The primary outcome, EFDs, is a frequently used measure for asthma control and reflects the multiple components of asthma disease burden. Although often informative in comparing the effects of long-term controller medications for asthma in patients with chronic symptoms, it could be argued that this measure might not have been sufficiently sensitive to detect treatment effects among children with an episodic disorder, such as severe intermittent asthma. However, there were no differences in prednisolone use between treatment groups, and thus our results would have been comparable had oral corticosteroid use, rather than EFDs, served as the primary outcome measure.
Regarding progression of the illness to the point of prednisolone use, it is possible that the initiation of high-dose budesonide or montelukast therapy after symptom onset and presumably after stimulation of the immune response usually triggered by an acute viral infection was incapable of changing the natural course of each such episode. Initiation of therapy too late into the development of an RTI might also have contributed to these findings. However, although it is possible that earlier initiation might have improved the treatment effects, most parents were not confident that some very early (and likely nonspecific) symptoms would be followed by wheezing and thus were directed to not start study medication for what appeared to be trivial symptoms. Alternatively, despite having 90% statistical power to detect a 0.5 SD unit difference in effect sizes for secondary outcomes, the lack of effect of study therapies on oral corticosteroid use might have been the result of inadequate statistical power for this secondary outcome.
The use of long-term control medication has been examined for the outcome of attenuating either the frequency, severity, or both of lower respiratory tract symptoms initiated by RTIs, with inconsistent findings. Some studies suggest that continuous use of ICSs for 4 to 6 months in young children with episodic wheezing does not reduce oral corticosteroid use or episode severity. [29] [30] [31] On the other hand, in preschool children with intermittent wheezing and positive modified API status, continuous use of ICSs for 2 years led to significant improvements in illness burden, including increasing EFDs and decreasing oral corticosteroid use, although it was accompanied by a statistically significant but mild and apparently transient reduction in linear growth velocity. 25 Daily administration of montelukast has been shown to reduce the rate of protocol-defined exacerbations, but not oral corticosteroid use, among 2-to 5-year-old children with intermittent asthma symptoms. 32 Our results suggest that the episodic use of an ICS (eg, budesonide) or an LTRA (eg, montelukast) can decrease an important source of respiratory morbidity, namely symptom burden, during acute RTIs in these children, particularly those with high risk of subsequent asthma (eg, with positive API status). Comparisons between intermittent and continuous therapy (or both) with these 2 controllers are needed, particularly among children at greatest risk for the persistence of asthma symptoms, to determine which of these 2 approaches is associated with greater efficacy, less parental and child burden, and fewer undesirable side effects.
This clinical trial was conducted to address a very important clinical question: Is the episodic use of an ICS or a leukotriene modifier effective in decreasing the morbidity associated with severe intermittent wheezing in preschool children? The clinical strategies examined in this trial are commonly used in clinical practice today. Our findings provide new insights into whether this treatment approach is rational in 3 important ways. First, this study demonstrates that, although there was no significant effect of these therapies on EFDs over a 1-year period, there was statistically significant, albeit modest, reduction in symptom burden during RTIs. Second, we were able to demonstrate that there was also variability in the response to these interventions, with children possessing risk factors for asthma at school entry (ie, positive API status) or greater illness severity (ie, use of oral corticosteroids in the preceding year) having a greater likelihood of experiencing a clinical benefit with these therapeutic strategies during RTIs. Finally, we have demonstrated that the 2 strategies, high-dose ICSs and LTRAs, provided very similar effects.
The role of commercial sponsors was limited to providing drugs and matched placebo, which they did after reviewing the drafted protocol. The text of the manuscript was made available to all commercial sponsors 2 weeks before finalization for comments. However, all final decisions regarding the study design and interpretation of data were made exclusively by the NHLBI CARE Network Steering Committee.
Clinical implications: Episodic use of budesonide or montelukast in preschool children with moderate-to-severe intermittent wheezing does not increase the proportion of EFDs but does decrease symptom severity during acute RTIs.
METHODS
Parents were instructed to call the clinical study center within 72 hours of initiation of study medication to discuss the scenario that prompted study medication use, as well as to describe the course of the illness.
Recognizing the variability in symptoms that parents might report as indicators of early RTI, before starting the main Acute Intervention Management Strategies trial, we conducted a pilot study of 28 parents of children 12 to 59 months of age with histories of recurrent severe wheezing in the setting of RTI to determine whether parents were able to identify a common set of signs and symptoms that precedes and signals the development of severe wheezing during an RTI in young children. Ninety-two percent of parents reported a sign or symptom that made them feel very certain that the most recent RTI would lead to significant wheezing, and 96% believed that the most recent episode was ''typical'' of what happens during an RTI that leads to wheezing. The most important signs or symptoms were cough (26.9%), breathing problems (23.1%), and noisy chest (15.4%) . Evaluated together, cough, breathing problem, or noisy chest were the first (82%) or second (93%) symptoms that led to use of inhaled bagonists. Overall, parents were confident in their ability to predict symptom progression for their child and reported that this progression was typical. Although most symptoms were chest related, there were no individual symptoms that occurred in the majority of children.
A formal written education module was reviewed with families at all study visits to help them in identifying symptoms consistent with an RTI and the symptoms seen early in the course of an exacerbation of severe intermittent asthma, as well as to ensure understanding of the study protocol and terminology used to describe symptoms. All scheduled contacts included diary card reviews and action plan review.
Study procedures
Percutaneous allergy skin testing to a panel of 8 inhalant and 3 food allergens was performed as described previously E1 with the MultiTest II (donated by Lincoln Diagnostics, Decatur, Ill) at the randomization visit, as was a comprehensive environmental survey, serum total IgE level, peripheral blood eosinophil percentage and count, and physical examination, including stadiometer measurements of recumbent length (participants 2 years of age) and standing height (participants >2 years of age). Quality-of-life assessments (PedsQL 4.0 Generic Scale E2 and Pediatric Asthma Caregiver's Quality of Life E3 ) were performed at randomization and final study visits.
Criteria for additional oral corticosteroid use
In the event that a patient had persistent respiratory symptoms (moderate-to-severe cough or wheeze for 5 days per week), a 4-day course of oral corticosteroid was prescribed in an attempt to reduce symptoms to a level comparable with that present before randomization (ie, intermittent). If symptoms persisted (moderate-to-severe cough or wheeze for 5 or more days per week), another course of oral corticosteroid was prescribed (to a maximum of 4 courses of oral corticosteroid during the study). If symptoms persisted after a second consecutive course (within 2 weeks of the previous course) of oral corticosteroids, the child was seen in the CARE clinic and evaluated for an alternative diagnosis for ongoing symptoms (eg, sinusitis). If an alternative diagnosis was not established, another 4-day course of oral corticosteroids was recommended (provided the child had not yet received 4 courses of oral corticosteroid during the study). If symptoms persisted after a third consecutive course of oral corticosteroids, the child was again seen in the CARE clinic and evaluated for an alternative diagnosis for ongoing symptoms. If an alternative diagnosis was not established, a fourth course of oral corticosteroids was recommended, and the child was assigned treatment failure status.
Treatment failure was defined as the occurrence of 4 oral corticosteroid courses, hospitalization or intubation for wheezing, hypoxic seizure, or a serious adverse event related to a study medication. Children meeting treatment failure status were withdrawn from the blinded phase of the trial and provided with budesonide, 0.5 mg once daily, for 6 weeks, after which their care was directed by the child's primary care provider with ongoing telephone contacts with the CARE center every 2 months until the end of the 12-month treatment period to ensure patient safety.
Statistical analyses
Clinic staff received a drug kit assignment for eligible participants through an automated, Web-based randomization application, which maintained the double blinding. Participant and study staff guesses at treatment assignments revealed no evidence of unblinding. (8.69-11.41) 11.50 (9.64-13.37 ) P value vs conventional therapy .12 .34 Nighttime cough ) P value vs conventional therapy .70 .45 Daytime 1 nighttime cough AUC 16.66 (14.23-19.10) 16.83 (14.56-19.10) 19.41 (16.29-22 .52) P value vs conventional therapy . 25 .29 Data are expressed as means (95% CIs).
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